3.6. Effects of topical and oral MQL administration on TMA-induced
AD symptoms
To evaluate the effects of MQL on Th2-mediated allergic diseases, we
used a TMA-induced AD-like mouse model. Since AD symptoms have been
known to occur through both external and internal factors, we
administered MQL treatment either topically or orally. After topical
treatment of MQL, ear thickness and infiltration of inflammatory cells
were reduced compared to the sham group (Fig. 6B and C) .
Furthermore, serum IgE levels were reduced in MQL10 group (Fig.
6D) . Next, to investigate the effects of MQL on T cell-mediated immune
responses, we measured Th1 (IL-12 and IFN-γ) and Th2 (IL-13) cytokine
production in the culture supernatant of DLNs and found that IL-13 and
IFN-γ production were significantly reduced by MQL treatment, but IL-12
was not changed (Fig. 6E-G) .
Next, we investigated effect of oral MQL administration on TMA-induced
AD. Similar to topical administration, oral MQL administration
ameliorated AD symptoms such as ear swelling and infiltration of
inflammatory cells in ear (Fig. 6I and J), and TMA-induced
serum IgE production was decreased by MQL compared with the sham group(Fig. 6K) . In DLNs, oral administration of MQL reduced IL-13
production and increased IL-12 (Fig. 6L and N) . These results
suggest that either topical or oral administration of MQL is a possible
treatment to attenuate the symptoms of AD.